Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer.
Latest Information Update: 16 Jul 2023
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 29 Oct 2020 Results published in the Clinical Cancer Research
- 12 Oct 2017 Results (n=213) of study developing and validating a tool to predict response by assessing association between pathological response and early changes in tumor infiltrating lymphocytes using patient data from NCT01973660 and NCT00524303 trials published in the Annals of Oncology
- 07 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.